Blue light therapy
What studies of blue light therapy found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 2 of 3 findings are C.
3 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Blue light therapy might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Blue light therapy · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Fatigue1 study · 43 people received blue light therapy Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (43 in all).
Studies with no comparison group43 in the study · 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week (2 days of pause · 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
Fatigue improved.
The evidence is very uncertain about the effect of blue light therapy on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (43 in all)
See the 1 study
-
LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection. (2024)
- People in the study
- 43 in the study
- Dose
- 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
- Outcome
- Fatigue Severity Scale (FSS) Fatigue Severity Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Autonomic symptoms1 study · 43 people received blue light therapy Little or no difference D
Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (43 in all).
Studies with no comparison group43 in the study · 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week (2 days of pause · 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
No clear change in autonomic symptoms.
The evidence is very uncertain about the effect of blue light therapy on autonomic symptoms in long COVID. Little or no difference · very low certainty D
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (43 in all)
See the 1 study
-
LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection. (2024)
- People in the study
- 43 in the study
- Dose
- 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
- Outcome
- systolic blood pressure
- Effect
- no clear difference
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Quality of life1 study · 43 people received blue light therapy Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (43 in all).
Studies with no comparison group43 in the study · 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week (2 days of pause · 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
Quality of life improved.
The evidence is very uncertain about the effect of blue light therapy on quality of life in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (43 in all)
See the 1 study
-
LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection. (2024)
- People in the study
- 43 in the study
- Dose
- 453 nm light (irradiance 40 mW/cm2), 15 min a day for 5 consecutive days each week (2 days of pause); 10 irradiations
- Outcome
- Dermatology Life Quality Index (DLQI) Dermatology Life Quality Index
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection.2024 · no comparison group · 43 in the study
Summary
This study enrolled 43 adults who had COVID-19 infection and reported a subjective feeling of fatigue 4 weeks after infection; participants were seen at the Dermatology, Paediatric Dermatology and Dermatological Oncology Clinic, Medical University of Lodz, Poland. All participants underwent 10 full-body blue light irradiations using Phlecs Full Body Blue 1.0 emitting 453 nm light (irradiance 40 mW/cm2) for 15 min a day for 5 consecutive days each week, with 2 days of pause. There was no comparison group; the authors state that another study with a placebo group is needed. Participants were assessed before starting and after the full irradiation regimen with the Fatigue Severity Scale (FSS), Short Form 36 Vitality Subscale (SF-36) and Dermatology Life Quality Index (DLQI); serum samples were taken from 20 individuals who provided additional consent. FSS decreased from 47.17 ±15.27 to 33.12 ±17.59 (p < 0.01), SF-36 increased from 57.10 ±27.67 to 76.07 ±25.77 (p < 0.01), and DLQI decreased from 7.62 ±6.49 to 3.95 ±5.02 (p < 0.01). Systolic blood pressure showed no significant change (p = 0.06), while diastolic blood pressure was significantly lower after 10 irradiations (from 81.2 to 78.5 mm Hg, p = 0.03). Harms and withdrawals were not reported. The authors state that patients should have been screened for depressive symptoms, that a placebo group is needed, and that more robust research with longer duration and larger group sizes is necessary.
- Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present.2021 · case report · 1 in the study
Summary
This case report described one patient with severe ME/CFS who presented to a rheumatologist’s office in August 2013 after becoming bedridden 4.5 years earlier. Over a 4-year period from September 2013 to August 2017, the patient received a changing protocol that included thyroid medications, antibiotics, antifungals, Hydroxychloroquine, colostrum, kelp, licorice root, fludrocortisone, EFT, EMDR, light therapy, and multiple herbs and supplements. No comparison group was reported. The report described function and symptoms over time. By the Spring of 2014 (~6 months after onset of treatment), she had improved enough to take a college course 1 day/week but was not well enough to drive. By February 2015 she was still predominantly housebound; she was doing better cognitively, but simple activity like walking was still too difficult on most days. She was back at the gym by April 2017 and going for walks daily. In August 2017 she was well enough to move out from her parents’ home and resume graduate school, and she had been stable for at least 6 months. Reported harms included Jarisch–Herxheimer reactions with severe joint and musculoskeletal pain, worsening fatigue, worsening cognitive function, migraines, and drops in blood pressure; doxycycline was discontinued. She also had severe reactions from all supplements, severe discomfort during EFT/EMDR sessions, and could not tolerate blue light more than 1–2 min without severe migraines. The authors stated it was not possible to determine whether improvements were mediated by treatments or spontaneous remission/placebo.